Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological mark... by Ivan Lolli, Daniele Santini, Rossana Berardi, Giuseppe Badalamenti, Toni Ibrahim, Alfredo Berruti, Alberto Bongiovanni, Chiara Liverani, Sara Pusceddu, Silvana Leo, Giovanni Di Meglio, Stefano Tamberi, Fabio Gelsomino, Francesca Pucci, Francesca Bergamo, Sergio Ricci, Flavia Foca, Stefano Severi, Mauro Cives, Davide Campana, Nicola Silvestris, Angela Buonadonna, Maria Pia Brizzi, Francesca Spada, Sara Cingarlini, Lorenzo Antonuzzo, Davide Pastorelli

Get full text